BeiGene Raises New Funds For Oncology Pipeline
This article was originally published in PharmAsia News
Executive Summary
Chinese bioventure BeiGene has raised additional funding from existing and new investors, providing it with new resources to take forward through early clinical trials several molecules for cancer.